Clinical Research (latest research)

Clinical research is an important component of the Center’s mission. Our clinical and laboratory staffs have initiated several research studies to answer many clinical questions. These studies help expand the scientific knowledge base and provide new technology to patients. Our clinical findings have been published in national journals and have played a role in advancing new knowledge to other Reproductive Medicine practices throughout the country. We are able to conduct this research only through the cooperation of our patients who are willing to participate in these studies. We dedicate all this advanced reproduction knowledge to them.

Current Research Being Done at the Center

Here are some of the exciting research projects taking place at the Center:

Limiting The Number of Times We Look At Embryos in the IVF Lab IRB #16-192R-3  
Principal Investigator: Alison Bartolucci

If you are a current or prospective patient of The Center for Advanced Reproductive Services, we invite you to join this research effort. In our continued commitment to innovation in the treatment of infertility, The Center for Advanced Reproductive Services has created a research study that will help us determine whether minimal evaluations of the embryos, performed only at the day of the embryo transfer, rather than observations on multiple days, would improve the overall development rate of the embryos. We are looking for 200 women aged at 18-40 years old to participate in this study. To join this research study, please speak with your doctor or a member of the clinical team. Click here to download our flyer with more information.

Celmatix Research Registry and Repository IRB #15-072-2
Principal Investigator: Dr. John Nulsen

In our commitment to innovation in the treatment of infertility, The Center for Advanced Reproductive Services has partnered with Celmatix to create an ambitious research registry and repository that will help us understand the genetic factors that underlie both fertility potential and infertility. Your contribution to this national registry will help us get one step closer to understanding the drivers of fertility potential and infertility, and could help millions of women just like you.

To participate in this research, you will be asked to donate a blood sample during a routine blood draw and allow researchers to review your and possibly your partner’s relevant medical information. This information will be added to a registry that will be used to help discover genetic factors associated with a woman’s fertility.

Any woman between the ages of 18-45 may be eligible to participate, including those who are seeking fertility preservation and/or help conceiving. Enrollment in this study is voluntary and participation will come at no additional cost. If you are interested in participating or learning more, please speak with a member of the CARS clinical staff or call our research coordinator Dr. Evelyn Neuber at 844-467-3483 Ext: 8019 or Alexandra Revoir at 844-467-3483 Ext:8033.

PROSPECT Study- Multicenter Registry with Eeva (Early Embryo Viability Assessment Test) IRB # 2014-AUX-012
Principal Investigator: Dr. Claudio Benadiva

The PROSPECT Research Study is currently recruiting patients at the Center for Advanced Reproductive Services, Farmington, CT. Eeva: The Early Embryo Viability Assessment Test is being studied for use in IVF laboratories to analyze early embryo development. The Eeva System is software that was designed to assess differences in early embryo growth and determine an embryo’s viability and the potential for further development. The Eeva Test was developed based on research conducted at Stanford University1 which discovered that early embryo growth events can predict embryo development and reflect the underlying health of the embryo.

The purpose of the PROSPECT research study is to collect data for further development and validation of the Eeva Test. The key patient eligibility criteria include but are not limited to:

• Women at least 18 years of age undergoing IVF treatment
• Planned Blastocyst (Day 5/Day 6) transfer
• Willing to have all fertilized eggs (2PN=2 pronuclei) imaged by Eeva
• Willing to provide written informed consent

If you are interested in participating in this research study, please contact Dr. Evelyn Neuber, Study Coordinator at (844) 467-3483 X8019 or eneuber@uconnfertility.com for more information. The Eeva System used in this clinical study has been cleared for marketing by the U.S. Food and Drug Administration (FDA) and has been granted marketing approval in Canada and New Zealand.

* * ** * * * * * **** * * * *
1. Wong et al. in Nature Biotechnology, 2010.
2.Diamond et al. J Assist Reprod Genet, May 2012

Dual Trigger Study

Those about to undergo and IVF cycle and deemed to be at risk for Ovarian hyperstimulation syndrome, (OHSS) development are invited to take part in this study.

The purpose of this study is to compare pregnancy rates and differences in OHSS development in IVF patients who receive low dose hCG at the time of Lupron trigger to those who receive low dose hCG after Lupron trigger, at the time of egg retrieval.  Ovarian hyperstimulation syndrome, OHSS, is a complication of in vitro fertilization caused by treatment with some fertility drugs.  When human chorionic gonadotropin, hCG, is given as the trigger in IVF treatments, it can lead to the development of OHSS.  The use of another fertility drug, Lupron, as the IVF trigger, prevents OHSS from developing, but may also lead to a reduction in pregnancy rates.  This study attempts to evaluate whether administration of hCG in conjunction with a Lupron trigger can be used to improve pregnancy outcomes while minimizing the risk of developing OHSS.  Dual Trigger is a double-blind study and enrolled participants will be placed randomly into one of two groups.  Participants will not receive financial compensation, however, some of the medications required for the IVF cycle will be provided free of charge.  Participation is voluntary, and enrolled patients can choose to withdraw from the study at any time.  The Center hopes to enroll a total of 80 participants for the Dual Trigger study.  For eligibility requirements or any additional information, please feel free to contact CARS clinical staff or the research coordinator at the number listed below.

Endometrial Biopsy Microarray Study

Healthy young women who will undergo an IVF cycle for the purpose of donating their eggs to another couple are invited to take part in this study.

The purpose of this study is to evaluate possible differences in the way certain genes are produced that may affect the lining of the uterus causing lower pregnancy rates, following the use of Lupron versus hCG for egg maturation in women undergoing controlled ovarian hyperstimulation (COH). Enrollment in the study is voluntary.  Participants will receive financial compensation.  For more information, please consult your CARS clinician. If you are interested in more information on these research projects or wish to discuss eligibility for participation, please contact your physician here at the Center or Dr. Evelyn Neuber, Clinical Research Coordinator at (844) 467-3482 Ext: 8019.